Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Apr 20 2024 8
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Podcast artwork

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at http://HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to [email protected]. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.

RSS feed Share
Copy RSS


Subscribe on Podcast Addict


2024 ACP Type 2 Diabetes Recommendations

Apr 20 2024 23 mins  
The American College of Physicians has released new recommendations in favor of SGLT2i and GLP-1 RA and against the use of DPP-4i as second-line therapies to metformin in adults with type 2 diabetes and inadequate glycemic control. Released on the first day of the ACP’s Internal Medicine Meeting 2024, the pair of recommendations reflect the findings from a systematic review and n

STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

Apr 20 2024 23 mins  
In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, tackle a pair of related topics: what the STEP HFpEF DM trial from ACC.24 means for the diabetes community and the need for fair and equitable allocation of incretin-based therapies in the face of ongoing drug shortages and overwhelming demand.

What to Know about Sequel Med Tech's twiist AID System, with Alan Lotvin, MD

Mar 30 2024 31 mins  
The diabetes community welcomed an additional tool to the armamentarium with the US Food and Drug Administration’s clearance of the twiist automated insulin delivery (AID) system on March 18, 2024. Cleared for use in patients aged 6 years and older with type 1 diabetes, the twiist, which is marketed by Sequel Med Tech, is billed as the first drug delivery system that directly mea

Hot Topics and Updates from ATTD 2024

Mar 30 2024 20 mins  
In the third and final recap episode from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes, hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into a series of topics from the meeting, including GLP-1 receptor agonist use and CGM technolog

T1D Glycemic Improvement and CRISTAL at ATTD 2024

Mar 26 2024 8 mins  
In this episode, hosts provide insight from automated insulin delivery updates from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes. The specific topics of note covered in this study include new data related to diabetes technology use from the Type 1 Diabetes (T1D) Exchange and a read-out of data from the CRISTAL trial.

FLOW Trial and Chronic Kidney Disease Updates, with Brendon Neuen, MBBS, PhD

Mar 22 2024 29 mins  
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives hosts are joined by Brendon Neuen, MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health. During the episode, Neuen talks about the FLOW trial, topline results, how the rapid advan

Dexcom Stelo and CGM Updates, with Jake Leach

Mar 22 2024 28 mins  
Hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives recorded a special edition episode with Jake Leach, chief operating officer of Dexcom. The episode itself represents a follow-up to a conversation a year ago at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2023, where Leach discussed the ongoing global rollo

Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD

Mar 18 2024 24 mins  
W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin t

SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD

Mar 02 2024 24 mins  
In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies. Chapters: 00:35 - Guest Introduction 01:10 - SELECT Results Overview 04:25 - Next Steps for Research

Understanding MARD, Comparing Popular CGM Sensors

Feb 29 2024 21 mins  
In this episode, the hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors. Video version: https://www.hcplive.com/view/diabetes-dialogue-understanding-mard-comparing-popular-cgm-sensors Key Highlights: 00:35 - The Myth of MARD 04:10 - Considerati